Seasonal influenza vaccination coverage in France during two influenza seasons (2007 and 2008) and during a context of pandemic influenza A(H1N1) in 2009

Objectives

To measure the seasonal influenza vaccination coverage rate (VCR) in France in 2009, year of the A(H1N1) influenza pandemic, by age and target disease and compare it with the VCR for the 2007 and 2008 influenza seasons.

Method

At the beginning of each annual seasonal vaccination campaign, the National Health Insurance, covering 86% of the French population, sends free influenza vaccination vouchers to at-risk beneficiaries aged under 65 suffering from diverse chronic diseases and to all individuals aged 65 and over (around 11 million). Vaccination is estimated from refund claims registered in the National Health Insurance Information System.

Results

The global VCR for the target population was 51% in 2007, 55.8% in 2008 and 56.9% in 2009. In 2009, the VCR for children under 10 years old was 24.3%, 28.1% in the 10-19 age range, 39.2% in the 20-64 age range and 63.3% for individuals aged 65 and over, of which 72.3% with a targeted chronic disease and 56.9% without. The inclusion of asthma as a target disease, lowered the global VCR for children under 10 years old (30.6% without asthma) but VCR increased proportionally with the number of annual refunds for drugs against asthma and chronic obstructive pulmonary disease. The 2009 vaccine uptake rates in target group children, adolescents, young adults and to a lesser extent the population aged 65 and over suffering from a chronic disease (particularly chronic respiratory disease), could have been positively impacted by the A(H1N1) influenza context.

Conclusion

The influenza VCR varies considerably according to age and target disease but globally remains inferior to the recommended 75% coverage rate. These results permit the detailed analysis of VCR distribution by disease and target group and highlights areas for reflection and action. Specific studies should be conducted in order to understand why the VCR is lower in certain target groups.     

Reduced risk of hospitalization associated with influenza vaccination in Canada

To evaluate the effectiveness of influenza vacation, we conducted analyses at both individual level and health region level. The association between influenza vaccination and hospital admission was examined among 128,677 subjects 12+ years of age who participated in a national survey in 2005. Both influenza and hospital admission proportions varied across health regions. Health regions with higher proportions of influenza vaccination had significantly lower proportions of hospitalization. A 10% increase in influenza vaccination less than 1 year ago was associated with a reduction of 11% in the risk of hospitalization over a 12-month time period at the health region level.     

A cross sectional survey to evaluate knowledge,attitudes and practices regarding seasonal influenza and influenza vaccination among diabetics in Pretoria,South Africa

BackgroundIn South Africa, influenza vaccination is recommended to all diabetics. However, vaccination coverage among diabetics remains low. Therefore, this study aimed to explore the knowledge, attitudes, and practices among people with diabetes in Pretoria regarding seasonal influenza and influenza vaccination.MethodA cross-sectional survey was conducted among type 1 and 2 diabetes mellitus patients who attended diabetic clinics in two major tertiary hospitals in Pretoria, South Africa from October to December 2015. The pilot-tested questionnaire consists of 32 quantitative questions that covered seasonal influenza and influenza vaccination in terms of the patient’s demographics, medical history and knowledge, attitudes and practices.ResultsA total of 292 completed questionnaires were received with a response rate of 70.0%. Of these, 162 participants (55.5%) believed that influenza is the same as common cold. While 96 (32.9%) participants were aware that they were at higher risk of complications of influenza, only 86 (29.5%) participants considered vaccination as an effective means in preventing serious influenza-related complication. Even though 167 (57.2%) participants had heard of the vaccine to prevent influenza, only 84 (28.8%) participants were previously vaccinated. Multivariate analysis shows that participants with good attitude score for influenza vaccination were 18.4 times more likely to be vaccinated compared with those with poor attitude score (OR =18.4, 95%CI. 5.28–64.10, p = .001). Among those previously vaccinated, advice from their doctors (82/84, 97.6%) was the main factor encouraging vaccination. Top reasons given by participants who had never been vaccinated before (208/292, 71.2%) include use of alternative protection (107/208, 51.4%) and that vaccination is not necessary because flu is just a minor illness (93/208, 44.7%).ConclusionUptake of seasonal vaccination among diabetics in Pretoria is low. Level of knowledge and perception are the main barriers to vaccination. Health care provider’s advice may be an important key predictor of previous influenza vaccination and they should continue to educate and encourage all diabetics to get vaccinated for influenza at least once yearly.     

Optimal targeting of seasonal influenza vaccination toward younger ages is robust to parameter uncertainty

Identification of the optimal vaccine allocation for the control of influenza requires consideration of uncertainty arising from numerous unpredictable factors, including viral evolution and diversity within the human population's immunity as well as variation in vaccine efficacy. The best policy must account for diverse potential outcomes based on these uncertainties. Here we used a mathematical model parametrized with survey-based contact data, demographic, and epidemiological data from seasonal influenza in the United States to determine the optimal vaccine allocation for five outcome measures: infections, hospitalizations, deaths, years of life loss, and contingent valuation. We incorporated uncertainty of epidemiological parameters and derive probability distributions of optimal age- and risk-specific allocation of vaccine. Our analysis demonstrated that previous recommendations of targeting schoolchildren (ages 5–17 years) and young adults (18–44 years) are generally robust in the face of uncertainty. However, when the outcome measure is to minimize deaths, years of life loss, or contingent valuation, uncertainty analysis identified scenarios under which it is optimal to target people at high risk for complications, even when vaccine are in abundance.     

High vaccination rates for seasonal and pandemic (A/H1N1) influenza among healthcare workers in Dutch general practice

In previous years, the influenza vaccination rate among Dutch general practitioners (GPs) was low (36% during the 2007/2008 season). Since 2008, yearly influenza vaccination has been actively recommended for GPs in The Netherlands. Moreover, in 2009 the Dutch government urged healthcare workers to receive additional vaccination against the pandemic influenza (A/H1N1). The effects of these recommendations are unknown. In February 2010, a questionnaire was mailed to random samples of GPs (n = 810) and GP-trainees (n = 300). Vaccination rates were determined and motives and barriers for vaccination were assessed. The response rates for GPs and GP-trainees were 83% and 90%, respectively. In total, 63% of the GPs were vaccinated against seasonal influenza and 85% against pandemic (A/H1N1) influenza. For GP-trainees, these percentages were 47% and 77%, respectively. With regard to the medical staff working in the respondents’ practices, 60% received the seasonal and 76% the pandemic (A/H1N1) influenza vaccine. Reducing the risk of transmitting the virus to vulnerable patients and the individual's personal protection were the most frequently reported motives for vaccination. Having no medical indication for influenza vaccination and the conviction of being protected against influenza because of frequent professional exposure to the virus were the most frequently mentioned reasons for not being vaccinated. In conclusion, the seasonal influenza vaccination rate among Dutch GPs has risen considerably since the previous survey and the vaccination rate against pandemic (A/H1N1) influenza was very high. Moreover, Dutch GPs were convinced that influenza vaccination will reduce the risk of transmitting the virus to their patients.     

Influenza vaccination rates in Ontario children: Implications for universal childhood vaccination policy

The aims of this study were to estimate influenza vaccination coverage for children during the 2006–2007 influenza season in Ontario, Canada, where universal vaccination is available, and to compare the rate among children aged 6–23 months with corresponding rates from other Canadian provinces that specifically target this high-risk group. We conducted a telephone survey of caregivers of children aged 6 months–11 years that included 4854 children from 3029 households. Ontario's vaccination rate (complete and partial coverage combined) for children aged 2–11 years was 28.3% (95% CI 26.3–30.5%) for healthy children and 36.8% (95% CI 31.4–42.5%) for those with chronic conditions. Immunization coverage of children aged 6–23 months was 24.0% (95% CI 20.6–27.7%) in Ontario, similar to Manitoba's rate of 24.1% but lower than rates in other provinces: Nova Scotia (35.5%), Quebec (41.8% for 1 year olds and 37.7% for 2 year olds during the 2005–2006 season), Saskatchewan (32.5%) and Alberta (52.2%). Universal vaccination in Ontario has achieved modest coverage in children aged 2–11 years, but has been less successful than targeted programs in vaccinating infants aged 6–23 months.     

Attitudes towards vaccination against seasonal influenza of health-care workers in primary health-care settings in Greece

Vaccination of health-care workers (HCWs) against seasonal influenza has been consistently recommended worldwide in order to prevent nosocomial transmission and ensure delivery of health-care services during outbreaks. We describe the effects of a nationwide campaign to promote influenza vaccination among HCWs working in primary health-care centers in Greece. During 2008–2009 the mean vaccination rate among HCWs in primary health-care centers was 22.8% (range: 0–100%), with a considerable variability among Health Districts (range: 12.66–54.68%). Logistic regression showed that history of previous influenza vaccination, influenza vaccination the previous season, being a physician and a larger number of employees were associated with increased vaccination rates. Main reason for vaccination was self-protection (75.90%), while main reasons for refusing vaccination were belief that they are not at risk for contracting influenza (44.5%), doubts about vaccine effectiveness (20.79%), and fear of vaccine adverse effects (20.33%).     

2015-2018年成都市6~35月龄儿童季节性流感疫苗接种率及安全性监测分析

目的 分析2015-2018年成都市6~35月龄儿童季节性流感疫苗（SIV）接种率及接种后疑似预防接种异常反应（AEFI）监测情况。方法 利用四川免疫规划信息管理系统和中国免疫规划信息管理系统收集2015年-2018年6~35月龄儿童SIV接种信息及接种SIV后报告的AEFI个案信息,并对收集到的信息进行分析。 结果 2015-2018年全市共接种儿童型SIV 516985剂次,357318人次,SIV接种率分别为22.41%、16.26%、21.64%和10.63%;全市2015-2018年共报告儿童型SIV疫苗AEFI 180例,总体报告发生率3.48/万剂,其中一般反应168例（占比93.33%）,异常反应6例（占比3.33%）,偶合症6例（占比3.33%）。 结论 成都市6~35月龄儿童SIV接种率较低,现有AEFI监测系统未发现不同于其他疫苗的不良反应。     

Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination,despite a positive trend in use

Sustainable demand for seasonal influenza vaccines is a component of national security strategies for pandemic preparedness. However, the ongoing COVID-19 pandemic has revealed many weaknesses in the capacity of countries to design and execute sustainable vaccination programs. An influenza pandemic remains a global threat and yet there is no global monitoring system for assessing progress towards influenza vaccination coverage targets. The International Federation of Pharmaceutical Manufacturers and Associations’ (IFPMA) Influenza Vaccine Supply International Task Force (IVS) developed a survey method in 2008 to estimate seasonal influenza vaccination coverage rates, which in turn serves as a crude estimate of pandemic preparedness. It provides evidence to guide expanded efforts for pandemic preparedness, specifically for increasing COVID-19 vaccine immunization levels. Furthermore, the results presented herein serve as a proxy for assessing the state of pandemic preparedness at a global and regional level. This paper adds data from 2018 and 2019 to the previous analyses. The current data show an upward or stable global trend in seasonal influenza vaccine dose distributed per 1,000 population with a 7% increase between 2017 and 2018 and 6% increase between 2018 and 2019. However, considerable regional inequities in access to vaccine persist. Three regions, Africa, the Middle-east, and Southeast Asia together account for 50% of the global population but only 6% of distributed seasonal influenza vaccine doses. This is an important finding in the context of the ongoing COVID-19 pandemic, as distribution of influenza vaccine doses in many ways reflects access to COVID-19 vaccines. Moreover, improving seasonal vaccine uptake rates is critical for optimizing the annual benefits by reducing the huge annual influenza-associated societal burdens and by providing protection to vulnerable individuals against serious complications from seasonal influenza infections.     

Improving influenza vaccination in chronically ill children using a tertiary-care based vaccination clinic: Is there a role for the live-attenuated influenza vaccine (LAIV)?

BackgroundChildren with underlying medical conditions should receive influenza vaccine (IV) yearly; yet this remains sub-optimal. We aimed to describe our experience with a tertiary-care hospital-based influenza vaccination clinic for this at-risk population.MethodsFrom October to December 2012, 2013, and 2014, we ran an influenza vaccination clinic at the Montreal Children's Hospital, where children with high-risk conditions come for their follow-up. Both injectable IV (IIV) and live-attenuated IV (LAIV) were offered free of charge to patients and their household contacts. Upon vaccination, parents were asked to fill a pre-piloted questionnaire.ResultsWe vaccinated a total of 2640 high-risk children and 1912 household members during the three influenza vaccination seasons. In 2012 and 2013, 631 and 630 patients with chronic illnesses were vaccinated, compared to 1379 in 2014. Caregivers preferred LAIV primarily because no needle was involved (49.0%) and because it was perceived as less painful (46.9%). LAIV was administered to 69% (2012), 55% (2013) and 47% (2014) of high-risk children. The main reason for not receiving LAIV was because it was contra-indicated. A small fraction of children previously vaccinated with LAIV who did not present any contraindication to LAIV opted for IIV: 12/101 (11.8%) in 2013 and 16/272 (5.9%) in 2014. In 2014, this was mainly due to a previous negative experience with LAIV (11/16).ConclusionHaving an influenza vaccination clinic on site at a tertiary care hospital, where children come for their scheduled visits, facilitates yearly influenza vaccination in children with chronic illnesses. LAIV is preferred by caregivers and patients, when not contraindicated.     

Healthcare worker’s attitude to seasonal influenza vaccination in the South Tyrolean province of Italy: barriers and facilitators

BackgroundSeasonal influenza vaccination (SIV) is an effective and safe way to prevent influenza. Public health institutions around the world consequently recommend SIV to certain groups at risk, including healthcare worker’s (HCWs). Even if SIV is free of charge, the vaccination coverage rate remains low, however. The aim of this study was to gain information on the sociodemographics, lifestyle and knowledge of HCWs associated with their attitude to SIV, also investigating the differences between different professional categories of HCW.MethodsA cross-sectional study was conducted over six consecutive weeks from October to December 2016. It was based on an anonymous online questionnaire administered to all employees (N = 9633) of the South Tyrolean Health Service. Coverage rates and attitudes to SIV were assessed by type of HCW. A logistic regression analysis was run to test the associations between SIV in the winter of 2015/2016 and potential predictors of the HCWs’ attitude to vaccination.ResultsIn all, 4091 employees (42.4% of the total) took part in the study. Statistically significant differences emerged between the different healthcare professions in terms of their reported vaccination rates and their attitudes to SIV. Among the different types of HCW, physicians had the highest rate of vaccination uptake. There were sociocultural and lifestyle factors associated with SIV in HCWs, as well as these worker’s professional roles and the ward where they worked. All the professionals agreed that specific training was the best way to improve HCW vaccination rates.ConclusionLow compliance with SIV among HCWs is attributable to numerous factors, some of which relate to their attitude to health issues. Commitment and accountability to patients and society should be further developed in HCWs. Specific training and information, also through informal scientific channels, should be provided to improve their knowledge of influenza and attitude to vaccination.     

Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/10

The results of Slovenian surveillance system of AEFI which was in place for the early detection and investigation of rare adverse events were analysed. The reports about AEFI obtained from physicians, and self-assessment questionnaires from vaccinated persons showed predominantly non-serious and expected side effects. Nine reports (3%) included serious AEFI. No deaths consequent to vaccination were reported. A total of 1170 AEFI were reported by physicians and 1030 by self-assessment. Overall, the most commonly reported AEFI either by physicians or persons were local site reactions (37.3% and 50.5%), tiredness (11.9% and 6.8%) and fever or malaise (10.8% and 6.3%). More than 100,000 people were vaccinated with pandemic vaccines in Slovenia. The type and the frequency of AEFI detected through Slovenian AEFI surveillance system are comparable to the results from other surveillance systems. The benefit-risk balance for the pandemic vaccines used in Slovenia remains positive.     

The importance of seasonal influenza vaccination for people with disabilities during the COVID-19 pandemic

A large proportion of Americans have at least one disability and yet people with disabilities face inequities in health and health care access. Factors associated with underlying disability and health, how they perceive and interact with the world, and where they live, or work may increase the risk people with disabilities face for illness or severe outcomes from seasonal influenza. Given the need to reduce the burden of respiratory illness on a healthcare system already overwhelmed by the COVID-19 pandemic, maximizing seasonal influenza vaccination coverage is particularly important in 2020–2021. It is critical this season to ensure equitable access to influenza vaccination for people with disabilities. Providing influenza vaccination services in the unique places where people with disabilities are living, working, or receiving care during the COVID-19 pandemic is crucial, as well as communicating effectively to people with different types of disabilities.     

2009-2010 seasonal and pandemic A (H1N1) influenza vaccination among healthcare workers

Influenza vaccination recommendations are traditionally met with low compliance by healthcare workers (HCWs). The aim of this study is to analyze influenza vaccination among HCWs following a vaccination strategy characterized by an increased effort to maximize the hospital vaccination rate. For this, 2009-2010 seasonal and pandemic influenza vaccination rates among 2739 HCWs at a tertiary university hospital were evaluated. The seasonal influenza vaccination rate was 26.7% (48.3% increase vs. 2008-2009, p = 0.0000), and 14.8% in the case of pandemic influenza. HCWs with direct patient contact showed similar seasonal (25.7%) and pandemic (15.4%) influenza vaccination rates compared to the overall rates. Physician vaccination displayed the highest rate, showing significant differences vs. total rate (38.3%, p = 0.0007 for seasonal, and 32.2%, p = 0.0000 for pandemic influenza). The areas in which the vaccination strategy was most active reflected a significant increase (32.6%, p = 0.0056 for seasonal, and 25.2%, p = 0.0000 for pandemic influenza). It therefore appears that more active campaigns might increase influenza vaccination among HCWs.     

Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario,Canada

BackgroundA number of highly effective COVID-19 vaccines have been developed and approved for mass vaccination. We evaluated the impact of vaccination on COVID-19 outbreak and disease outcomes in Ontario, Canada.MethodsWe used an agent-based transmission model and parameterized it with COVID-19 characteristics, demographics of Ontario, and age-specific clinical outcomes. We implemented a two-dose vaccination program according to tested schedules in clinical trials for Pfizer-BioNTech and Moderna vaccines, prioritizing healthcare workers, individuals with comorbidities, and those aged 65 and older. Daily vaccination rate was parameterized based on vaccine administration data. Using estimates of vaccine efficacy, we projected the impact of vaccination on the overall attack rate, hospitalizations, and deaths. We further investigated the effect of increased daily contacts at different stages during vaccination campaigns on outbreak control.ResultsMaintaining non-pharmaceutical interventions (NPIs) with an average of 74% reduction in daily contacts, vaccination with Pfizer-BioNTech and Moderna vaccines was projected to reduce hospitalizations by 27.3% (95% CrI: 22.3% − 32.4%) and 27.0% (95% CrI: 21.9% − 32.6%), respectively, over a one-year time horizon. The largest benefits of vaccination were observed in preventing deaths with reductions of 31.5% (95% CrI: 22.5% − 39.7%) and 31.9% (95% CrI: 22.0% − 41.4%) for Pfizer-BioNTech and Moderna vaccines, respectively, compared to no vaccination. We found that an increase of only 10% in daily contacts at the end of lockdown, when vaccination coverage with only one dose was 6%, would trigger a surge in the outbreak. Early relaxation of population-wide measures could lead to a substantial increase in the number of infections, potentially reaching levels observed during the peak of the second wave in Ontario.ConclusionsVaccination can substantially mitigate ongoing COVID-19 outbreaks. Sustaining population-wide NPIs, to allow for a sufficient increase in population-level immunity through vaccination, is essential to prevent future outbreaks.     

Seasonal influenza vaccine dose distribution in 195 countries (2004–2013): Little progress in estimated global vaccination coverage

Seasonal influenza is an important disease which results in 250,000–500,000 annual deaths worldwide. Global targets for vaccination coverage rates (VCRs) in high-risk groups are at least 75% in adults ≥65 years and increased coverage in other risk groups. The International Federation of Pharmaceutical Manufacturers and Associations Influenza Vaccine Supply (IFPMA IVS) International Task Force developed a survey methodology in 2008, to assess the global distribution of influenza vaccine doses as a proxy for VCRs. This paper updates the previous survey results on absolute numbers of influenza vaccine doses distributed between 2004 and 2013 inclusive, and dose distribution rates per 1000 population, and provides a qualitative assessment of the principal enablers and barriers to seasonal influenza vaccination. The two main findings from the quantitative portion of the survey are the continued negative trend for dose distribution in the EURO region and the perpetuation of appreciable differences in scale of dose distribution between WHO regions, with no observed convergence in the rates of doses distributed per 1000 population over time. The main findings from the qualitative portion of the survey were that actively managing the vaccination program in real-time and ensuring political commitment to vaccination are important enablers of vaccination, whereas insufficient access to vaccination and lack of political commitment to seasonal influenza vaccination programs are likely contributing to vaccination target failures. In all regions of the world, seasonal influenza vaccination is underutilized as a public health tool. The survey provides evidence of lost opportunity to protect populations against potentially serious influenza-associated disease. We call on the national and international public health communities to re-evaluate their political commitment to the prevention of the annual influenza disease burden and to develop a systematic approach to improve vaccine distribution equitably.     

Impacts of expanding provider choice for free flu vaccination among the elderly in Korea

The Korean government, to increase the vaccination rates, implemented the policy expanding provider choice for free seasonal influenza vaccine for the elderly through contracting the provision of immunization to the private sector in 2015. Using the annual nationally representative individual between 2014–2017, this study explores the impacts of the policy change by using a difference-in-differences approach. Results show that influenza vaccine uptake at private clinics increases by 12 percentage points after the policy change. However, this effect is offset by a reduction in uptake at public health centers by 13 percentage points. As a result, we find no evidence that the policy increases overall vaccination coverage among the elderly. These results indicate that policymakers need to explore the reasons for vaccine hesitancy before delivering interventions.     

Longitudinal,population-based cohort study of prenatal influenza vaccination and influenza infection in childhood

BackgroundInfluenza vaccination is recommended to protect mothers and their infants from influenza infection. Few studies have evaluated the health impacts of in utero exposure to influenza vaccine among children more than six months of age.MethodsWe used probabilistically linked administrative health records to establish a mother–child cohort to evaluate the risk of influenza and acute respiratory infections associated with maternal influenza vaccination. Outcomes were laboratory-confirmed influenza (LCI) and hospitalization for influenza or acute respiratory infection (ARI). Adjusted hazard ratios (aHRs) accounted for child’s Aboriginal status and were weighted by the inverse-probability of treatment.Results14,396 (11.5%) children were born to vaccinated mothers. Maternally vaccinated infants aged < 6 months had lower risk of LCI (aHR: 0.33; 95% CI: 0.13, 0.85), influenza-associated hospitalization (aHR: 0.39; 95% CI: 0.16, 0.94) and ARI-associated hospitalization (aHR: 0.85; 95% CI: 0.77, 0.94) compared to maternally unvaccinated infants. With the exception of an increased risk of LCI among children aged 6 months to < 2 years old following first trimester vaccination (aHR: 2.28; 95% CI: 1.41, 3.69), there were no other differences in the risk of LCI, influenza-associated hospitalization or ARI-associated hospitalization among children aged > 6 months.ConclusionStudy results show that maternal influenza vaccination is effective in preventing influenza in the first six months and had no impact on respiratory infections after two years of age.     

Cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women

ObjectiveTo evaluate the cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women using data from three recent influenza seasons in the United States.Design, setting, and participantsWe developed a decision-analytic model following a cohort of 5.2 million pregnant women and their infants aged <6 months to evaluate the cost-effectiveness of vaccinating women against seasonal influenza during pregnancy from a societal perspective. The main outcome measures were quality-adjusted life-year (QALY) gained and cost-effectiveness ratios. Data sources included surveillance data, epidemiological studies, and published vaccine cost data. Sensitivity analyses were also performed. All costs and outcomes were discounted at 3% annually.Main outcome measuresTotal costs (direct and indirect), effects (QALY gains, averted case numbers), and incremental cost-effectiveness of seasonal inactivated influenza vaccination among pregnant women (cost per QALY gained).ResultsUsing a recent benchmark of 52.2% vaccination coverage among pregnant women, we studied a hypothetical cohort of 2,753,015 vaccinated pregnant women. With an estimated vaccine effectiveness of 73% among pregnant women and 63% among infants <6 months, QALY gains for each season were 305 (2010–2011), 123 (2011–2012), and 610 (2012–2013). Compared with no vaccination, seasonal influenza vaccination during pregnancy was cost-saving when using data from the 2010–2011 and 2012–2013 influenza seasons. The cost-effectiveness ratio was greater than $100,000/QALY with the 2011–2012 influenza season data, when CDC reported a low attack rate compared to other recent seasons.ConclusionsInfluenza vaccination for pregnant women can reduce morbidity from influenza in both pregnant women and their infants aged <6 months. Seasonal influenza vaccination during pregnancy is cost-saving during moderate to severe influenza seasons.